A nano particle vector comprised of poly lactic-co-glycolic acid and monophosphoryl lipid A and recombinant Mycobacterium avium subsp paratuberculosis peptides stimulate a pro-immune profile in bovine macrophages

• DOI: 10.1111/jam.13491
• Publication Date: 2017-05-14T09:31:36Z
• Authors: C.D. Souza; J.P. Bannantine; W.C. Brown; M.G. Norton; W.C. Davis; J.K. Hwang; P. Ziaei; G.S. Abdellrazeq; M.V. Eren; J.R. Deringer; E. Laws; M.C.D. Cardieri
• Keywords: Anaplasma marginale; Mycobacterium avium subsp. paratuberculosis; 0301 basic medicine; 570; 03 medical and health sciences; 615; peptide vaccine; monophosphoryl lipid A; PLGA; Agriculture; 3. Good health

We evaluated the potential of a nanoparticle (NP) delivery system to improve methods of delivery of candidate peptide-based vaccines for Paratuberculosis in cattle.Peptides derived from Mycobacterium avium subsp. paratuberculosis (Map), and the pro-inflammatory monophosphoryl lipid A (MPLA) were incorporated in polymeric NPs based on poly (d,l-lactide-co-glycolide) (PLGA). The PLGA/MPLA NPs carriers were incubated with macrophages to examine their effects on survival and function. PLGA/MPLA NPs, with and without Map antigens, are efficiently phagocytized by macrophages with no evidence of toxicity. PLGA/MPLA NP formulations did not alter the level of expression of MHC I or II molecules. Expression of TNFα and IL12p40 was increased in Map-loaded NPs. T-cell proliferation studies using a model peptide from Anaplasma marginale demonstrated that a CD4 T-cell recall response could be elicited with macrophages pulsed with the peptide encapsulated in the PLGA/MPLA NP.These findings indicate PLGA/MPLA NPs can be used as a vehicle for delivery and testing of candidate peptide-based vaccines.These results will assist on more in depth studies on PLGA NP delivery systems that may lead to the development of a peptide-based vaccine for cattle.